Market closed
Sarepta Therapeutics/$SRPT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Ticker
$SRPT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
1,314
Website
SRPT Metrics
BasicAdvanced
$11B
Market cap
97.53
P/E ratio
$1.22
EPS
0.80
Beta
-
Dividend rate
Price and volume
Market cap
$11B
Beta
0.8
52-week high
$173.25
52-week low
$89.92
Average daily volume
1.1M
Financial strength
Current ratio
3.839
Quick ratio
2.451
Long term debt to equity
106.953
Total debt to equity
115.87
Interest coverage (TTM)
4.23%
Management effectiveness
Return on assets (TTM)
1.51%
Return on equity (TTM)
12.27%
Valuation
Price to earnings (TTM)
97.531
Price to revenue (TTM)
7.031
Price to book
9.3
Price to tangible book (TTM)
9.52
Price to free cash flow (TTM)
-24.008
Growth
Revenue change (TTM)
48.45%
Earnings per share change (TTM)
-115.61%
3-year revenue growth (CAGR)
36.46%
3-year earnings per share growth (CAGR)
-41.57%
What the Analysts think about SRPT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Sarepta Therapeutics stock.
SRPT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SRPT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SRPT News
AllArticlesVideos
Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku
Reuters·1 day ago
FDA's new accelerated approval guidance to benefit rare disease drug development, analysts believe
Proactive Investors·1 week ago
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Sarepta Therapeutics stock?
Sarepta Therapeutics (SRPT) has a market cap of $11B as of December 22, 2024.
What is the P/E ratio for Sarepta Therapeutics stock?
The price to earnings (P/E) ratio for Sarepta Therapeutics (SRPT) stock is 97.53 as of December 22, 2024.
Does Sarepta Therapeutics stock pay dividends?
No, Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next Sarepta Therapeutics dividend payment date?
Sarepta Therapeutics (SRPT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.